Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization – The older the average person alive today becomes, the more instances of neurodegeneration are observed world-wide. Alzheimer’s disease is the most common neurodegenerative disorder preferentially affecting older individuals with 26.6 million cases recorded in 2006. It is estimated that worldwide prevalence will rise to 100 million cases by 2050 . There is currently no effective (...)